Source:http://linkedlifedata.com/resource/pubmed/id/20133660
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2010-2-17
|
| pubmed:abstractText |
Treatment strategies for severe cases of pandemic influenza have focused on antiviral therapies. In contrast, passive immunotherapy with convalescent blood products has received limited attention. We consider the hypothesis that a passive-immunotherapy program that collects plasma from a small percentage of recovered adults can harvest sufficient convalescent plasma to treat a substantial percentage of severe cases during a pandemic. We use a mathematical model to estimate the demand and supply of passive immunotherapy during an influenza pandemic in Hong Kong. If >5% of 20- to 55-year-old individuals recovered from symptomatic infection donate their plasma (donor percentage > 5%), >67% of severe cases can be offered convalescent plasma transfusion (treatment coverage > 67%) in a moderately severe epidemic (R (0) < 1.4 with 0.5% of symptomatic cases becoming severe). A donor percentage of 5% is comparable to the average blood donation rate of 38.1 donations per 1,000 people in developed countries. Increasing the donor percentage above 15% does not significantly boost the convalescent plasma supply because supply is constrained by plasmapheresis capacity during most stages of the epidemic. The demand-supply balance depends on the natural history and transmission dynamics of the disease via the epidemic growth rate only. Compared to other major cities, Hong Kong has a low plasmapheresis capacity. Therefore, the proposed passive-immunotherapy program is a logistically feasible mitigation option for many developed countries. As such, passive immunotherapy deserves more consideration by clinical researchers regarding its safety and efficacy as a treatment for severe cases of pandemic influenza.
|
| pubmed:grant | |
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-10697061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-10720501,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-15602562,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-16013892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-16079251,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-16515368,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-16585506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-16642006,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-16940336,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-17535101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-17914053,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-18366252,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-18647634,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-19433588,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-19554084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-19679750,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-19696313,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20133660-19745114
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1091-6490
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:day |
16
|
| pubmed:volume |
107
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3269-74
|
| pubmed:dateRevised |
2011-3-1
|
| pubmed:meshHeading |
pubmed-meshheading:20133660-Age Factors,
pubmed-meshheading:20133660-Blood Donors,
pubmed-meshheading:20133660-Disease Outbreaks,
pubmed-meshheading:20133660-Hong Kong,
pubmed-meshheading:20133660-Humans,
pubmed-meshheading:20133660-Immunization, Passive,
pubmed-meshheading:20133660-Influenza, Human,
pubmed-meshheading:20133660-Models, Theoretical
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic.
|
| pubmed:affiliation |
Department of Community Medicine and School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China. joewu@hku.hk
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|